An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
We describe the first case of a 36 year-old male patient with a somatotropin and thyreotropin secreting pituitary adenoma, co-treated by a long-acting releasing somatostatin analog (Octreotide) and a GH receptor antagonist (Pegvisomant). The patient normalized his biological disease activity reflected by hormone levels but his tumor size remained unchanged as measured by MRI. The co-treatment was well tolerated and induced a synergic effect on IGF1 levels that allowed us to use low doses of both therapies.
Meas
T
T
Department of Endocrinology, Hospital Saint-Louis, Assistance- Publique Hôpitaux de Paris, 1, avenue Claude Vellefaux 75010 Paris, France. taly.meas@lrb.ap-hop-paris.fr
Sobngwi
E
E
Vexiau
P
P
Boudou
P
P
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D042882:Gallstones / Q000150:complications; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery; D013972:Thyrotropin / Q000378:metabolism*
D000970:Antineoplastic Agents; D019382:Human Growth Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; C406545:pegvisomant; D015282:Octreotide